Clinical Trials Logo

Clinical Trial Summary

This is a 10-year multi-center, global, observational study to further characterize the safety profile of pegvaliase, including hypersensitivity reactions, long-term safety and tolerability, and the effectiveness of the additional risk minimization measures (aRMMs) (European Union (EU) only) in subjects receiving pegvaliase for the treatment of PKU. Subjects for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment (incident-users) or have previously started treatment with pegvaliase at the date of enrollment (prevalent-users) are eligible for participation in this study.


Clinical Trial Description

This is a 10-year multi-center, global, observational study to further characterize the safety profile of pegvaliase, including hypersensitivity reactions, long-term safety and tolerability, and the effectiveness of the aRMMs (EU only) in subjects receiving pegvaliase for the treatment of PKU. Subjects for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment (incident-users) or have previously started treatment with pegvaliase at the date of enrollment (prevalent-users) are eligible for participation in this study. Once the subject has been enrolled, the investigator (ie, subject's primary physician) will be asked to provide information about the subject's medical history, treatment(s) received to manage their blood Phe levels, treatment with pegvaliase, and concomitant medication use. The investigator will also be asked to provide evaluation of the following safety concerns: Acute systemic hypersensitivity reaction, Anaphylaxis, Angioedema, Serum sickness, Severe hypersensitivity reaction, Severe or Persistent arthralgia, Severe injection site reaction, Hypophenylalaninemia and other protocol-defined safety events, following the initiation of pegvaliase therapy. There are no protocol-mandated visits or procedures associated with this study. Enrolled subjects should be followed per routine clinical practice at the institution based upon their diagnosis, with clinical outcomes assessed at regular intervals (typically every month during the induction and titration phases of pegvaliase treatment and every 6 months once the maintenance phase is reached). No experimental treatment or assessments are planned as part of this observational study. An Independent Adjudication Committee (IAC) will periodically review protocol-defined safety events, including Acute systemic hypersensitivity reaction and Serum sickness. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05813678
Study type Observational
Source BioMarin Pharmaceutical
Contact 165-501 Program Director
Phone 1-800-983-4587
Email medinfo@bmrn.com
Status Recruiting
Phase
Start date June 6, 2022
Completion date November 1, 2033

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04480567 - AAV Gene Therapy Study for Subjects With PKU Phase 1/Phase 2
Completed NCT03694353 - Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU Phase 3
Completed NCT04086511 - PANDA: PKU Amino Acid Evaluation
Completed NCT02440932 - Impact of Phenylketonuria-type Diet on Appetite, Appetite Hormones and Diet Induced Thermogenesis N/A
Completed NCT01617070 - Effects of Kuvan on Melatonin Secretion Phase 4
Completed NCT03505125 - A Non-Interventional Interview Study of Phenylketonuria (PKU) Adults
Terminated NCT01806051 - A Pilot Study on Diurnal Variation N/A
Active, not recruiting NCT05270837 - Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria Phase 3
Completed NCT01889862 - Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU Phase 3
Completed NCT02009904 - Simple Breath Test to Examine Phenylalanine Metabolism
Recruiting NCT06305234 - A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
Recruiting NCT03309345 - Body Composition, Energy Intake and Expenditure in People With Phenylketonuria N/A